Compare · DXCM vs SWAV
DXCM vs SWAV
Side-by-side comparison of DexCom Inc. (DXCM) and Shockwave Medical Inc. (SWAV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SWAV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.11B, about 5.9x SWAV ($4.73B).
- DXCM has hit the wire 26 times in the past 4 weeks while SWAV has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 21 for SWAV).
- Company
- DexCom Inc.
- Shockwave Medical Inc.
- Price
- $72.84+0.38%
- $334.80-0.01%
- Market cap
- $28.11B
- $4.73B
- 1M return
- +20.73%
- -
- 1Y return
- -14.94%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2019
- News (4w)
- 26
- 0
- Recent ratings
- 25
- 21
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Shockwave Medical Inc.
ShockWave Medical, Inc., a medical device company, engages in developing and commercializing intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
Latest SWAV
- Sonder Capital Closes its Second Fund and Announces Participation from Major Healthcare Systems
- Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors
- Bruker Appoints Laura Francis to its Board of Directors
- Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner
- SEC Form 15-12G filed by Shockwave Medical Inc.
- Francis Laura returned 4,784 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Moll Frederic H returned 287,521 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Papiernik Antoine returned 34,913 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Sainz Maria returned 5,328 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SEC Form S-8 POS filed by Shockwave Medical Inc.